PERKINELMER INC - PKI STOCK NEWS

EUROIMMUN, a subsidiary of PerkinElmer (NYSE:PKI), announced the inclusion of its Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) test in the CDC's pre-vaccination screening for the Dengvaxia vaccine. This test is crucial for ensuring that children aged 9-16, who have a laboratory-confirmed previous dengue infection, can access the vaccine in dengue-endemic areas. In 2019, dengue cases reached record levels, emphasizing the need for effective diagnostic solutions. The assay focuses on virus-specific antibodies, enabling better vaccination strategies against dengue disease.

PerkinElmer reported 4Q 2021 revenue of $1.36 billion, reflecting a 1% reported growth but a -9% organic growth. GAAP EPS from continuing operations was $1.41, down from $3.38 in 4Q 2020. For the full year, GAAP revenue reached $5.067 billion, up from $3.783 billion in 2020, boasting a 32% increase. The company also announced its 2022 guidance, projecting first-quarter revenue between $1.17-$1.19 billion and full-year revenue of $4.42-$4.50 billion.

The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of $0.07 per share on January 27, 2022. The dividend will be payable on May 13, 2022 to shareholders on record by the close of business on April 22, 2022. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and employs over 16,000 people globally, serving customers in 190 countries.

PerkinElmer, Inc. (NYSE: PKI) anticipates exceeding its fourth quarter 2021 revenue and earnings guidance. Expected adjusted earnings per share is at least $2.40, with fourth quarter COVID-related revenue projected at approximately $320 million. Non-COVID organic growth for the same quarter is estimated at 10%, leading to an annual growth of roughly 16%. Total projected revenues for 2021 are around $5.0 billion, with substantial contributions from both Diagnostics and Discovery segments.

PerkinElmer (NYSE: PKI) is set to present virtually at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The company's CEO, Prahlad Singh, will discuss strategic priorities and provide an update on operations. A live audio webcast will be accessible via the provided link, and a replay will be available on the PerkinElmer Investor Relations website for 30 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 16,000 staff globally, serving customers in 190 countries.

PerkinElmer, a leader in health innovations, has launched the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 for accelerated detection of SARS-CoV-2 variants, including Omicron. The kit enhances sequencing throughput and reduces turnaround time by three hours for 96 samples through advanced normalization beads. It incorporates 1,536 Unique Dual Index barcodes, allowing for the sequencing of 6,000 libraries in a single flow cell, lowering costs. This initiative aims to support SARS-CoV-2 surveillance efforts amid the ongoing pandemic.

PerkinElmer, Inc. (NYSE: PKI) announced that its SARS-CoV-2 RT-PCR assays remain effective despite the emergence of the Omicron variant of concern.

With over 30 reported mutations in the S gene, the company's assays do not target this gene and are unaffected by these changes. In silico assessments indicate no impact on diagnostic accuracy from the Omicron variant.

The company emphasizes the importance of reliable diagnostics amid ongoing concerns regarding transmissibility and vaccine resistance. PerkinElmer's solutions include a comprehensive SARS-CoV-2 portfolio.

PerkinElmer, a global leader in health innovation, will present at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET. Prahlad Singh, the Company’s CEO, will discuss strategic priorities and provide a company update. Interested parties can register for the event here. A webcast will be available on PerkinElmer's Investor website, with a replay accessible for 90 days post-event.

PerkinElmer, a global leader in health innovation, will present at the virtual 2021 Stifel Healthcare Conference on November 16, 2021, at 8:40 a.m. ET. Senior VP and CFO Jamey Mock will discuss the company's strategic priorities. Interested participants can register for the event here. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after.